Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Penn Capital Management Company LLC

Penn Capital Management Company LLC lowered its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 281,918 shares of the company’s stock after selling 26,073 shares during the quarter. Mirum Pharmaceuticals makes up about 1.8% of Penn Capital Management Company LLC’s investment portfolio, making the stock its 3rd largest holding. Penn Capital Management Company LLC’s holdings in Mirum Pharmaceuticals were worth $22,322,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Cullen Frost Bankers Inc. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. MCF Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the period. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at about $33,000. Comerica Bank raised its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Finally, Quarry LP bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at about $41,000.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $98.90 on Wednesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $43.30 and a twelve month high of $114.99. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The company has a 50-day simple moving average of $96.54 and a two-hundred day simple moving average of $88.93. The stock has a market capitalization of $6.03 billion, a price-to-earnings ratio of -7.27 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same quarter last year, the firm earned ($0.30) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.11 EPS for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the completion of the sale, the chief executive officer owned 194,309 shares in the company, valued at $17,872,541.82. The trade was a 17.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joanne Quan sold 7,287 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This trade represents a 27.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 76,806 shares of company stock worth $7,064,616. 22.87% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on MIRM shares. Evercore reissued an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Citizens Jmp reissued a “market outperform” rating and issued a $132.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 21st. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Finally, HC Wainwright set a $185.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $137.08.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.